MX2023001501A - Vacuna tau para tratamiento de enfermedad de alzheimer. - Google Patents

Vacuna tau para tratamiento de enfermedad de alzheimer.

Info

Publication number
MX2023001501A
MX2023001501A MX2023001501A MX2023001501A MX2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A MX 2023001501 A MX2023001501 A MX 2023001501A
Authority
MX
Mexico
Prior art keywords
tau
disease
alzheimer
compositions
peptides
Prior art date
Application number
MX2023001501A
Other languages
English (en)
Spanish (es)
Inventor
Tarlochan S Nijjar
Robin Barbour
Wagner Zago
Gene Kinney
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2023001501A publication Critical patent/MX2023001501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023001501A 2020-08-07 2021-05-19 Vacuna tau para tratamiento de enfermedad de alzheimer. MX2023001501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062971P 2020-08-07 2020-08-07
PCT/US2021/033189 WO2022031342A1 (en) 2020-08-07 2021-05-19 Tau vaccine for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2023001501A true MX2023001501A (es) 2023-03-08

Family

ID=80118379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001501A MX2023001501A (es) 2020-08-07 2021-05-19 Vacuna tau para tratamiento de enfermedad de alzheimer.

Country Status (12)

Country Link
US (1) US20230302127A1 (cg-RX-API-DMAC10.html)
EP (1) EP4192583A4 (cg-RX-API-DMAC10.html)
JP (2) JP2023536746A (cg-RX-API-DMAC10.html)
KR (1) KR20230080398A (cg-RX-API-DMAC10.html)
CN (1) CN117751132A (cg-RX-API-DMAC10.html)
AR (1) AR122129A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021321206A1 (cg-RX-API-DMAC10.html)
CA (1) CA3188458A1 (cg-RX-API-DMAC10.html)
IL (1) IL300346A (cg-RX-API-DMAC10.html)
MX (1) MX2023001501A (cg-RX-API-DMAC10.html)
TW (1) TW202221022A (cg-RX-API-DMAC10.html)
WO (1) WO2022031342A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4218794A3 (en) * 2009-06-10 2023-09-13 New York University Immunological targeting of pathological tau proteins
CN102596236B (zh) * 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP3275461A1 (en) * 2011-09-19 2018-01-31 Axon Neuroscience SE Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field
WO2015098963A1 (ja) * 2013-12-26 2015-07-02 東亞合成株式会社 カルレティキュリンの発現促進方法および該方法に用いられる合成ペプチド
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016154522A1 (en) * 2015-03-25 2016-09-29 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
KR20250058066A (ko) * 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
SG11201910066QA (en) * 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
JP2020536946A (ja) * 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
TWI859197B (zh) * 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體

Also Published As

Publication number Publication date
WO2022031342A1 (en) 2022-02-10
KR20230080398A (ko) 2023-06-07
EP4192583A1 (en) 2023-06-14
EP4192583A4 (en) 2025-02-12
CN117751132A (zh) 2024-03-22
JP2026120788A (ja) 2026-07-22
AU2021321206A1 (en) 2023-03-09
US20230302127A1 (en) 2023-09-28
JP2023536746A (ja) 2023-08-29
IL300346A (en) 2023-04-01
AR122129A1 (es) 2022-08-17
CA3188458A1 (en) 2022-02-10
TW202221022A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
PH12022553234A1 (en) Multi-epitope vaccine for the treatment of alzheimer`s disease
MX2023003009A (es) Vacuna de beta-amiloide para el tratamiento de la enfermedad de alzheimer.
MX2023001503A (es) Vacuna de multiples epitopos para tratamiento de la enfermedad de alzheimer.
AR122129A1 (es) Vacuna de tau para el tratamiento de la enfermedad de alzheimer
Castillo-Carranza et al. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds
MX2023003008A (es) Vacuna de multiples epitopos para el tratamiento de la enfermedad de alzheimer.
US12570735B2 (en) Compositions and methods for treating inflammasome related diseases or conditions
Gonsette et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing-remitting Multiple Sclerosis (ASIIMS) trial
JPWO2019156137A5 (cg-RX-API-DMAC10.html)
MX2023003007A (es) Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias.
US20250255939A1 (en) Methods and compositions for inducing neural plasticity
US20180344808A1 (en) Haptoglobin derivative for treatment of sepsis and acetaminophen-induced liver damage
JP2016539911A5 (cg-RX-API-DMAC10.html)
CN105612179B (zh) 单克隆olfml-3抗体及其用途
JP2022121359A (ja) シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト
WO2025080877A3 (en) Therapeutic peptides
US20230181692A1 (en) Compositions for use in the treatment of neurological disease
US10660935B2 (en) Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
WO2016060190A1 (ja) アミロイドβ蛋白質により誘発される認知障害の治療剤
AR122126A1 (es) Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer
WO2023231402A1 (zh) UbV.E4B蛋白的医药用途、药物组合物
Gonsette et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon b in relapsing–remitting Multiple Sclerosis (ASIIMS) trial
CN118510532A (zh) 治疗或预防4R tau蛋白病用肽
Prosperini PHARMACOLOGICAL TREATMENTS OF HIGHLY-ACTIVE RRMS: THE ROLE OF MONOCLONAL ANTIBODIES.
JP2023534619A (ja) 真菌感染症の治療のための組成物及び方法